Cargando…

Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial

Patients hospitalized for acute heart failure experience poor health status, including a high burden of symptoms and physical limitations, and poor quality of life. SGLT2 (sodium-glucose cotransporter 2) inhibitors improve health status in chronic heart failure, but their effect on these outcomes in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kosiborod, Mikhail N., Angermann, Christiane E., Collins, Sean P., Teerlink, John R., Ponikowski, Piotr, Biegus, Jan, Comin-Colet, Josep, Ferreira, João Pedro, Mentz, Robert J., Nassif, Michael E., Psotka, Mitchell A., Tromp, Jasper, Brueckmann, Martina, Blatchford, Jonathan P., Salsali, Afshin, Voors, Adriaan A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9311476/ https://www.ncbi.nlm.nih.gov/pubmed/35377706 http://dx.doi.org/10.1161/CIRCULATIONAHA.122.059725

Ejemplares similares

Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial
por: Biegus, Jan, et al.
Publicado: (2022)

Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial
por: Voors, Adriaan A., et al.
Publicado: (2022)

Sodium–glucose co‐transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial
por: Tromp, Jasper, et al.
Publicado: (2021)

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
por: Voors, Adriaan A., et al.
Publicado: (2022)

Rationale and design of the EMPERIAL‐Preserved and EMPERIAL‐Reduced trials of empagliflozin in patients with chronic heart failure
por: Abraham, William T., et al.
Publicado: (2019)

Effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on potassium handling in patients with acute heart failure
por: Beusekamp, Joost C., et al.
Publicado: (2021)

Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial( )
por: Doehner, Wolfram, et al.
Publicado: (2022)

Hepatorenal dysfunction identifies high‐risk patients with acute heart failure: insights from the RELAX‐AHF trial
por: Biegus, Jan, et al.
Publicado: (2019)

Potential contribution of haemoconcentration to changes in lipid variables with empagliflozin in patients with type 2 diabetes: A post hoc analysis of pooled data from four phase 3 randomized clinical trials
por: Lund, Søren S., et al.
Publicado: (2021)

Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR‐Reduced
por: Ferreira, João Pedro, et al.
Publicado: (2022)

Iron deficiency in chronic heart failure: case‐based practical guidance
por: Lam, Carolyn S. P., et al.
Publicado: (2018)

Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA‐REG OUTCOME trial
por: Fitchett, David, et al.
Publicado: (2021)

Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2022)

Systematic review and meta‐analysis of intravenous iron‐carbohydrate complexes in HFrEF patients with iron deficiency
por: Sindone, Andrew, et al.
Publicado: (2022)

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(®) trial
por: Fitchett, David, et al.
Publicado: (2016)

Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study
por: Nishimura, Rimei, et al.
Publicado: (2015)

Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction
por: Butler, Javed, et al.
Publicado: (2022)

Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial
por: Packer, Milton, et al.
Publicado: (2020)

Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure
por: Boorsma, Eva M., et al.
Publicado: (2020)

Effect of ferric carboxymaltose on calculated plasma volume status and clinical congestion: a FAIR‐HF substudy
por: Okonko, Darlington O., et al.
Publicado: (2019)

Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta‐analysis of data from randomized placebo‐controlled trials
por: Salsali, A., et al.
Publicado: (2016)

Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial
por: Butler, Javed, et al.
Publicado: (2021)

The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study
por: Comin-Colet, Josep, et al.
Publicado: (2013)

Síndrome de tako-tsubo asociado con COVID-19
por: Oyarzabal, Loreto, et al.
Publicado: (2020)

Tako-tsubo syndrome associated with COVID-19
por: Oyarzabal, Loreto, et al.
Publicado: (2020)

Tratamiento neurohormonal en miocardiopatía de tako-tsubo precipitada por COVID-19. Respuesta
por: Oyarzabal, Loreto, et al.
Publicado: (2021)

Neurohormonal treatment in tako-tsubo cardiomyopathy precipitated by COVID-19. Response
por: Oyarzabal, Loreto, et al.
Publicado: (2021)

Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study
por: Metra, Marco, et al.
Publicado: (2010)

Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial
por: Roden, Michael, et al.
Publicado: (2015)

Pathophysiological pathways related to high plasma growth differentiation factor 15 concentrations in patients with heart failure
por: Ceelen, Daan, et al.
Publicado: (2022)

Characteristics and clinical outcomes of patients with acute heart failure with a supranormal left ventricular ejection fraction
por: van Essen, Bart J., et al.
Publicado: (2022)

Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial
por: Butler, Javed, et al.
Publicado: (2021)

Use of potassium-binder patiromer for up-titration of renin–angiotensin–aldosterone system inhibition therapy in a patient with chronic heart failure and reduced ejection fraction followed in a multidisciplinary integrated chronic care management programme: a case report
por: Jiménez-Marrero, Santiago, et al.
Publicado: (2020)

Getting ahead of the game: in-hospital initiation of HFrEF therapies
por: Biegus, Jan, et al.
Publicado: (2022)

Pathophysiology and Treatment Opportunities of Iron Deficiency in Heart Failure: Is There a Need for Further Trials?
por: Tkaczyszyn, Michał, et al.
Publicado: (2023)

Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial
por: Anker, Stefan D., et al.
Publicado: (2020)

Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA‐REG OUTCOME
por: Pellicori, Pierpaolo, et al.
Publicado: (2020)

Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction
por: Butler, Javed, et al.
Publicado: (2021)

Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR‐Preserved trial
por: Packer, Milton, et al.
Publicado: (2021)

Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction: A Post Hoc Analysis of the EMPEROR-Preserved Trial
por: Butler, Javed, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gfubd3rbj74umjql4ce7i16h1k